Projects

Vice director
Ing. Zdena Sulová, DrSc.

International

Finished
  • P-glycoproteín Mediated Multidrug Resistance in Radiation-Associated Hematological Malignancies Following the Chernobil Accident.
    Program: NATO
    Duration: 1. 1. 2007 – 31. 12. 2008

National

Current
  • DNA methylation changes accompanying the development of multidrug resistance
    Program: VEGA
    Duration: 1. 1. 2024 – 31. 12. 2027
  • Use of recombinant enzymes with thioglucosidase activity for the transformation of plant glucosinolates and their analogues into biologically active substances with preventive and suppressive effect on neoplasia development
    Program: SRDA
    Duration: 1. 7. 2023 – 30. 6. 2027
  • -
    Program: VEGA
    Duration: 1. 1. 2023 – 31. 12. 2026
  • The effect of UV-B radiation on DNA damage and repair mechanisms in the P-glycoprotein-expressing L1210 cell line
    Program: VEGA
    Duration: 1. 1. 2022 – 31. 12. 2025
  • Biochip systems for targeted glycan analysis of biomarkers for biomedical and biotechnological applications
    Program: SRDA
    Duration: 1. 7. 2021 – 30. 6. 2025
  • Monitoring the interconnection of molecular events leading to the development of multidrug resistance in leukemic cells
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
Finished
  • Defense mechanisms of microbial and animal cells in reducing their sensitivity to plant defensive compounds
    Program: SRDA
    Duration: 1. 7. 2020 – 30. 6. 2024
  • Multidrug resistance of leukemia cells - Phenotype caused by interference of multimodal molecular reasons
    Program: SRDA
    Duration: 1. 7. 2020 – 30. 6. 2024
  • Study of alteration in leukemia cells phenotype after induction of ABCB1 membrane transporter
    Program: VEGA
    Duration: 1. 1. 2019 – 31. 12. 2022
  • The application of myrosinase for sulforaphane activation in development of a novel product exhibiting cancer prevention effects
    Program: SRDA
    Duration: 1. 7. 2017 – 30. 6. 2021
  • Study of changes in expression of some regulatory and functional proteins connected with the presence of P-gp protein in leukemic cells
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2020
  • Novel synergistic antitumour properties of nuclear retinoid X receptor (RXR) agonists as a consequence of the conditional RXR-RAR heterodimer formation in human breast cancer cells
    Program: SRDA
    Duration: 1. 7. 2016 – 30. 6. 2020
  • Defense mechanisms of neoplastic cells against chemical stress
    Program: SRDA
    Duration: 1. 7. 2016 – 30. 6. 2020
  • Biochips and biosensors for glycorecognition, their development, prepararion and application in cancer research
    Program: SRDA
    Duration: 1. 7. 2015 – 30. 6. 2019
  • The effect of endoplasmic reticulum stress inductors and proteaosome inhibitors on leukemia cell line L1210, SKM-1 and MOLM-13 with induced P-glycoprotein overexpression
    Program: VEGA
    Duration: 1. 1. 2016 – 31. 12. 2018
  • Changes of leukemia cells drug sensitivity induced by changes of membrane drug transporters expression profile.
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2018
  • Possible dual function of P-glycoprotein in leukemia cells: efflux pump and regulatory protein
    Program: SRDA
    Duration: 1. 7. 2015 – 31. 7. 2018
  • Multidrug resistance of leukemia cells to diverse drugs
    Program: VEGA
    Duration: 1. 1. 2013 – 31. 12. 2016
  • -
    Program: EU Structural Funds Research & Development
    Duration: 8. 10. 2015 – 31. 12. 2015
  • Preparation of nanostructured interfaces, their integration with bioelements and subsequent use
    Program: SRDA
    Duration: 1. 7. 2012 – 31. 12. 2015
  • Antitumour effect of biologically active ligands of nuclear retinoid X receptor heterodimers in tissue carcinoma cell lines
    Program: SRDA
    Duration: 1. 7. 2012 – 31. 12. 2015
  • Building a Competency Centre for research and development in the field of molecular medicine
    Program: EU Structural Funds Research & Development
    Duration: 1. 10. 2011 – 31. 10. 2015
  • Center of excellence for glycomics
    Program: EU Structural Funds Research & Development
    Duration: 1. 11. 2010 – 31. 12. 2014
  • Alternation in cell metabolism asocciated with drug transporter P-glycoprotein overexpression in leukemia cells
    Program: SRDA
    Duration: 1. 5. 2011 – 31. 10. 2014
  • Diagnostics of socially important disorders in Slovakia, based on modern biotechnologies
    Program: EU Structural Funds Research & Development
    Duration: 1. 11. 2010 – 31. 10. 2013
  • Effect of overexpression of P-glycoprotein and development of multidrug resistance on some aspects of metabolism
    Program: VEGA
    Duration: 1. 1. 2010 – 31. 12. 2012
  • Changes of leukemia cells associated with P-glycoprotein mediated multidrug resistance development
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2011
  • Biomembranes: Membrane structure and dynamics in relation to cell functions
    Program: SRDA
    Duration: 1. 7. 2008 – 31. 10. 2011
  • Biomembranes: structure and dynamics of biological membranes related to cell functions
    Program: SRDA
    Duration: 1. 7. 2008 – 30. 6. 2011
  • Overexpression of P-glycoprotein and associated changes in spectrum and levels oligo- and polysaccharides
    Program: SRDA
    Duration: 1. 6. 2008 – 31. 12. 2010
  • Changes of neoplastic cell metabolism associated with development of p-glycoprotein mediated miltidrug resistance induced by adaptation of sensitive cells to drugs
    Program: VEGA
    Duration: 1. 1. 2007 – 31. 12. 2009
  • Phenotype of multidrug resistance associated with overexpresion of mdr 1 - p-glycoprotein in neoplastic cells
    Program: VEGA
    Duration: 1. 1. 2006 – 1. 12. 2008
  • Calcium homeostasis and signalization in cells - structural, functional and metabolic relations during developmentof patologic changers
    Program: SRDA
    Duration: 1. 1. 2005 – 1. 12. 2007
Employees